Related Experiment Video
Updated: Aug 9, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
1Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA. wpope@mednet.ucla.edu
Neurology
|April 26, 2006
Abstract:
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
